Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor

Figures & data

Table 1 Inclusion and Exclusion Criteria

Inclusion Criteria	Exclusion Criteria
Informed consent	Uncontrolled IOP (>25 mmHg)
≥18 years of age	Prior retinal scaring, cataracts, or vitreous hemorrhage
Ability to complete study	Intravitreal steroid treatment within prior 6 months
Diagnosis of center involving DME or RVO	MI, TIA, or CVA within prior 90 days
Currently treated with Aflibercept or Ranibizumab	Diagnosis of Glaucoma
“Dry” SD-OCT (macula thickness less than 315 µm and reestablishment of foveal pit)
Baseline fluorescein angiography
VA >6/30

Figure 1 OCT measured retinal ganglion cell volume (mm³) in all groups, black bar represents median value, open circles are outliers, statistical significance is noted above relevant groups (**p<0.01, ***p<0.001).

Abbreviations: RVO, retinal vein occlusion; DME, diabetic macular edema.

Figure 2 LogMAR BCVA in RVO (retinal vein occlusion) patient’s treated and unaffected eye, black bar is the median value, open circles are outliers, statistical significance is noted above relevant groups (**p<0.01).

Figure 3 Camblobs contrast sensitivity in all groups, black bar is the median value, open circles are outliers, statistical significance is noted above relevant groups (**p<0.01).

Abbreviations: RVO, retinal vein occlusion; DME, diabetic macular edema.

Figure 4 Pelli-Robson contrast sensitivity in all groups, black bar is the median value, open circles are outliers, statistical significance is noted above relevant groups (**p<0.01).

Abbreviations: RVO, retinal vein occlusion; DME, diabetic macular edema.